Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
118 results about "Neuro degeneration" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The term neurodegeneration is a combination of two words - "neuro," referring to nerve cells and "degeneration," referring to progressive damage. The term "neurodegeneration" can be applied to several conditions that result in the loss of nerve structure and function. This deterioration gradually causes a loss...
Pharmaceutical composition for suppression of apoptosis and method for delivering the same
InactiveUS20080132450A1Minimizing and avoiding systemic side effectEffectively suppress apoptosis and the development of diseasesAntibacterial agentsSenses disorderDiseaseMedicine
The present invention relates to a pharmaceutical composition for treating heart diseases, neurodegenerative diseases, and diseases and conditions caused by apoptosis, which contains a conjugate of a heat shock protein (Hsp) and a protein transduction domain (PTD). According to the present invention, PTD-Hsp70 effectively suppresses apoptosis under low-oxygen conditions.
Owner:FORHUMANTECH CO LTD
Method of treating a patient with a neurodegenerative disease using ultrasound
InactiveUS7211054B1Promote wound healingPromote healingUltrasound therapyChiropractic devicesDiseaseNitric oxide
The present invention provides methods for treating patients with ultrasound to promote healing. In particular, the present invention provides a method for improving blood flow to ischemic tissue by applying ultrasound to ischemic tissue. The invention also provides a method for increasing nitric oxide production in tissue by applying ultrasound to tissue.
Owner:UNIVERSITY OF ROCHESTER
Cytomodulating peptides and methods for treating neurological disorders
InactiveUS20040186052A1Reducing neural cell deathReduce cell deathNervous disorderPeptide/protein ingredientsNeuritisNeuro degeneration
Compositions and methods are provided for inhibiting neuronal cell death and the loss of neuronal contacts resulting from acute and chronic neurological disorders, including neurodegenerative and neuroinflammatory diseases. The subject compositions and methods utilize RDP-58 compositions capable of providing a direct neuroprotective effect on neuronal cells in conjunction with the inhibition of autoimmune and inflammatory processes.
Owner:SANGSTAT MEDICAL
Complement inhibition for improved nerve regeneration
ActiveUS20100143344A1Improve regenerative abilityPromote regenerationBiocideNervous disorderDiseaseNervous system
The present invention relates to methods and medicaments used for treating conditions that require axonal regeneration, e.g. in mammals affected by injury or disease of the central or peripheral nervous system. The medicaments used in these methods facilitate axonal regeneration by inhibition of the complement system. Conditions requiring axonal regeneration that may be treated in accordance with the invention include physical injuries as well as neurodegenerative disorders of the peripheral or central nervous system.
Owner:REGENESANCE
Methods of treatment and prevention of neurodegenerative diseases and disorders
The present invention provides compostions and methods useful for treating and preventing neurodegenerative disease and neurologically related disorders by inhibition of Lp-PLA2. The compositions and methods are useful for treating and preventing diseases and disorders with abnormal blood brain barrier (BBB) function, for example neurodegenerative diseases with a permeable BBB, such as but not limited to, Alzheimer's Disease, Huntington's Disease, Parkinson's Disease and Vascular Dementia.
Owner:UNIV OF MEDICINE & DENTISTRY OF NEW JERSEY +1
Extended primary retinal cell culture and stress models, and methods of use
A cell culture system related to extended in vitro culture of mature retinal cells and methods for preparing the cell culture system are provided. Also provided is a retinal cell culture stress model related to extended in vitro culture of mature retinal cells in the presence of a stressor and methods for using the cell culture stress model. The invention provides a cell culture system comprising a long-term culture of mature retinal cells, without requiring addition of other types of non-retinal cells such as purified glia, or cells isolated from ciliary bodies within the eye, and the addition of a stressor such as light, A2E, cigarette smoke condensate, glutamate, or hydrostatic pressure. Methods for identifying bioactive agents that alter viability, neurodegeneration, or survival of retinal cells using the retinal cell culture stress system are also provided.
Owner:ACUACELA INC
Complement inhibition for improved nerve regeneration
ActiveUS8703136B2Improve regenerative abilityPromote regenerationNervous disorderPeptide/protein ingredientsDiseaseNervous system
The present invention relates to methods and medicaments used for treating conditions that require axonal regeneration, e.g. in mammals affected by injury or disease of the central or peripheral nervous system. The medicaments used in these methods facilitate axonal regeneration by inhibition of the complement system. Conditions requiring axonal regeneration that may be treated in accordance with the invention include physical injuries as well as neurodegenerative disorders of the peripheral or central nervous system.
Owner:REGENESANCE
Methods for treating macular degeneration with topiramate
InactiveUS6949518B1Prevent macular degenerationBiocideCarbohydrate active ingredientsNeuro degenerationTopiramate
A method for treating macular degeneration and / or treating optic nerve degeneration of a patient comprises administering topiramate with a dosage pharmaceutically effective to suppress degeneration or induce growth of new optic nerve fibers over a sustained period.
Owner:CHU PAO HSIEN +1
Methods and compositions for protecting against neurotoxicity of a neurotoxic agent, and improving motor coordination associated with a neurodegenerative condition or disease
InactiveUS20120121656A1Reduce neurotoxicityBiocideOrganic active ingredientsPhosphorylationDisease cause
Provided are methods for protecting against or reducing neurotoxicity of exposure to a neurotoxic agent, comprising administering an electrokinetically altered aqueous fluid as provided herein in an amount sufficient to provide for neuroprotection against the neurotoxic agent, preferably where protecting against or reducing loss of motor coordination in the subject exposed to the neurotoxin is afforded. In certain aspects, protecting or reducing neurotoxin-mediated neuronal apoptosis is afforded, and / or activating or inducing at least one of PI-3 kinase and Akt phosphorylation in neurons is afforded. Preferably, administering the fluid comprises administering the fluid prior to exposure to the neurotoxic agent. Additionally provided are methods for preserving or improving motor coordination in a subject having a neurodegenerative condition or disease, comprising administering an electrokinetically altered aqueous fluid as provided herein in an amount sufficient to provide for preserving or improving motor coordination in the subject.
Owner:REVALESIO CORP
Therapeutic contact lens for pseudo-aphakic eyes and/or eyes with retinal neuro-degeneration
The object of the invention is a contact lens for pseudo-aphakic eyes and / or eyes with macular and retinal degeneration, its main characteristic being the application of a yellow filter to a standard contact lens, with the purpose of protecting the eye from the short wavelength radiation of the visible spectrum (lower than 500 nm).This invention avoids the difficulties and risks of existing techniques, providing protection to the cataract-operated eye and improving natural protection in eyes with retinal neuro-degeneration, through the simple application of a contact lens.The invention consists of the combination of a standard contact lens and yellow filter, which absorbs short wavelengths of 350 / 500 nm, both its components being appropriate for use in the human eye.
Owner:UNIV COMPLUTENSE DE MADRID
The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases
InactiveUS20100173960A1Preventing and reducing aggregation of AβMaintaining synaptic functionBiocideNervous disorderNeuro degenerationProtein folding
The invention relates generally to novel compositions and methods comprising one or more cyclohexanehexol and one or more NSAID. The compositions and methods provide beneficial effects in the treatment and prevention of diseases involving a disorder in protein folding and / or aggregation, and / or amyloid formation, deposition, accumulation, or persistence, in particular neurodegenerative diseases.
Owner:WARATAH PHARMA INC
Use of apotosis inhibiting compounds in degenerative neurological disorders
The invention provides methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain associated with a neurodegenerative diseases that is characterized by an excess buildup of buildup of intracellular protein aggregates. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding an inhibitor of apoptosis protein (IAP) to cells in the region.
Owner:MEIRAGTX UK II LTD
Combined regulation of neural cell production
InactiveUS7048934B2Increase the number ofIncrease productionNervous disorderPeptide/protein ingredientsNeurulationDisease
This invention relates to a method of selectively producing neural cells, including neurons or glial cells, in vitro or in vivo. Also provided are methods of treating or ameliorating neurodegenerative disease or medical conditions by producing neural cells. Thus, a combination of factors is used to achieve two steps: increasing the number of neural stem cells and instructing the neural stem cells to selectively become neurons or glial cells.
Owner:STEM CELL THERAPEUTICS
Method, system and software arrangement for reconstructing formal descriptive models of processes from functional/modal data using suitable ontology
A method, system and software arrangement in accordance with an exemplary embodiment of the present invention are provided to extract descriptive narrative from numerical experimental data augmented with ontological controlled vocabulary. One exemplary application of such system, method and software arrangement is in organizing gene-expression time course data in terms of biological processes that may be activated and deactivated as the biological system responds to its normal or perturbed environment. The present invention may also have biological applications to drug-or-vaccine discovery, understanding behavior of a cell in an altered diseased state (e.g., cancer, neuro-degeneration or auto-immune disease, etc.), genetically modifying a natural wild-type organism, genetic-engineering, etc. Other exemplary applications may include understanding neural behavior, market behavior of a population of users interacting on the Internet, etc.
Owner:NEW YORK UNIV
Differential diagnosis of neurodegeneration
InactiveUS20040014142A1Specific detectionSpecific quantificationDisease diagnosisBiological testingSpecific detectionSynuclein
The present invention relates to new methods for the specific detection, quantification and / or differential diagnosis of neurodegeneration in an individual making use of a combination assay detecting at least three neurological markers in one or more body fluids of said individual, the type and degree of neurodegeneration being reflected in the quantitative changes in the level of all of said neurological markers compared to the control sample. The present invention also relates to methods for the detection of Rab3a, SNAP25 and alpha-synuclein in cerebrospinal fluid and to the use of these methods in a combination assay for specific detection, quantification and / or differential diagnosis of neurodegeneration.
Owner:INNOGENETICS NV
Benzofurans as suppressors of neurodegeneration
InactiveUS7008950B1Low toxicityImprove breathabilityBiocideNervous disorderSuppressorAliphatic hydrocarbon
A compound of the formula: wherein R1 and R2 each is H or a hydrocarbon group which may be substituted, or R1 and R2 form a 3- to 8-membered carbo or heterocyclic ring which may be substituted; R3 is H, a lower alkyl which may be substituted or an aromatic group which may be substituted; R4 is (1) an aromatic group which may be substituted, (2) an aliphatic hydrocarbon group substituted by an aromatic group which may be substituted, which hydrocarbon group may be further substituted or (3) an acyl; X and Y each is oxygen or sulfur which may be oxidized; and ring A is a benzene ring which may be further substituted, or a salt thereof, is useful for an agent for suppressing neurodegeneration.
Owner:TAKEDA PHARMA CO LTD
Methods for diagnosis of Alzheimer's Disease in blood samples
InactiveUS7598049B2Improve the level ofLower Level RequirementsMicrobiological testing/measurementDisease diagnosisMild cognitive impairment (MCI)Neuro degeneration
The inventors have discovered a collection of proteinaceous biomarkers (“AD biomarkers) which can be measured in peripheral biological fluid samples to aid in the diagnosis of neurodegenerative disorders, particularly Alzheimer's disease and mild cognitive impairment (MCI). The invention further provides methods of identifying candidate agents for the treatment of Alzheimer's disease by testing prospective agents for activity in modulating AD biomarker levels.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV +2
Down syndrome critical region 1-like protein
The invention provides a Down syndrome critical region 1-like 1 protein, its encoding cDNAs, and antibodies that specifically bind the protein. The invention also provides for the use of these compositions in the diagnosis, prognosis, treatment and evaluation of progression and treatment of neurodegenerative disorders.
Owner:INCYTE
Hydroxybutyrate ester and medical use thereof
ActiveCN102164884AIncrease alertnessImprove cognitive functionNervous disorderOrganic chemistryBlood plasmaFatty acid
A compound which is 3-hydroxybutyl 3-hydroxybutyrate enantiomerically enriched with respect to (3R) hydroxybutyl (3R)-hydroxybutyrate of formula (I): is an effective and palatable precursor to the ketone body (3R)-hydroxybutyrate and may therefore be used to treat a condition which is caused by, exacerbated by or associated with elevated plasma levels of free fatty acids in a human or animal subject, for instance a condition where weight loss or weight gain is implicated, or to promote alertness or improve cognitive function, or to treat, prevent or reduce the effects of, neuro degeneration, free radical toxicity, hypoxic conditions or hyperglycaemia.
Owner:OXFORD UNIV INNOVATION LTD +1
Preparation and utility of opioid analgesics
The present disclosure is directed to modulators of opiate- and / or NMDA receptors and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the use of such compounds for the treatment and / or management of pain, anxiety, neurodegeneration, drug dependence, coughing, muscular tension, and / or glaucoma and any other condition in which it is beneficial to modulate an opiate- and / or NMDA receptor.
Owner:AUSPEX PHARMA INC
Method, system and software arrangement for reconstructing formal descriptive models of processes from functional/modal data using suitable ontology
ActiveUS20110119221A1Improve insightsEnhanced informationSemantic analysisChaos modelsModal dataThe Internet
Owner:NEW YORK UNIV
Ghrelin Protects Substantia Nigra Dopamine Neurons
A method of treating neurodegeneration of substantia nigra pars compacta (SNpc) dopamine neurons and compositions therefor are provided.
Owner:YALE UNIV
Method to Diagnose and Measure Vascular Drainage Insufficiency in the Central Nervous System
InactiveUS20120277572A1Increased post-stimulus undershootReturn to normal activitiesSensorsBlood flow measurementDiseaseBiological activation
Neurodegenerative diseases, such as multiple sclerosis, may be caused or aggravated by insufficient venous draining from the central nervous system. Functional MRI measures the surge of blood flow into localized regions of cerebral cortex in response to activation of those regions by performing visual, auditory or executive tasks. These fMRI measurements are based on blood-oxygen-level dependence. The resulting fMRI / BOLD data is converted to hemodynamic response data and analyzed to determine any abnormality in the hemodynamic response data. Vascular drainage insufficiency is identified in the presence of abnormal hemodynamic response data. Abnormal hemodynamic response data can be determined by a negative trough in a graph of the HDR data or by the duration, depth, or area of the negative trough.
Owner:HUBBARD DAVID R
Treatment of mci and alzheimer's disease
ActiveUS20110118299A1Avoid it happening againReduce processBiocideNervous disorderNifedipineMild cognitive impairment (MCI)
The present invention provides, among other things, therapeutic compositions and methods that can effectively treat, slow or prevent a neurological disease (e.g., a neurodegenerative disease, e.g., mild cognitive impairment (MCI) or Alzheimer's disease (AD)), in particular, based on therapeutically effective amount of nifedipine, oxidized or nitroso nifedipine derivatives, lactam (e.g., a compound of formula (Ic) or (Ic-i), e.g., NFD-L1), thyroxine (T4), triiodothyronine (T3) and combinations thereof.
Owner:UNIV OF KENTUCKY RES FOUND
Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders
InactiveUS20100255099A1Preventing cell lossAvoid cell deathBiocideOrganic active ingredientsImmediate releaseBULK ACTIVE INGREDIENT
The present invention generally relates to use of a stable solid pharmaceutical compositions that includes a clavulanate as the pharmaceutically active ingredients in an immediate-release or an extended-release solid dosage form. The composition can be used in a method of treating a neurodegenerative disease, providing neuroprotection, or preventing neuronal cell loss or death. Exemplary neurodegenerative diseases include Parkinson's disease, Alzheimer's disease and multiple sclerosis.
Owner:REXAHN PHARMA INC
Therapeutic contact lens for pseudo-aphakic eyes and/or eyes with retinal neuro-degeneration
ActiveUS20060238703A1Good colorMore lightSpectales/gogglesEye treatmentCataract surgeryNeuro degeneration
The object of the invention is a contact lens for pseudo-aphakic eyes and / or eyes with macular and retinal degeneration, its main characteristic being the application of a yellow filter to a standard contact lens, with the purpose of protecting the eye from the short wavelength radiation of the visible spectrum (lower than 500 nm). This invention avoids the difficulties and risks of existing techniques, providing protection to the cataract-operated eye and improving natural protection in eyes with retinal neuro-degeneration, through the simple application of a contact lens. The invention consists of the combination of a standard contact lens and yellow filter, which absorbs short wavelengths of 350 / 500 nm, both its components being appropriate for use in the human eye.
Owner:UNIV COMPLUTENSE DE MADRID
Methods of treating neurodegenerative disorders and diseases
InactiveUS20120010196A1Inhibiting growth cone collapseBiocideNervous disorderIntracellular signallingScreening method
This invention is directed to a novel method of treating neurodegenerative disorders and diseases. Another, related aspect of this invention is directed to a screening method of identifying compounds that can be used to treat neurodegenerative disorders and diseases. The foregoing aspects of the invention particularly relate to neurodegenerative disorders and diseases have degeneration of neuronal axons as part of their pathologies. The method of treatment involves administering a pharmaceutical formulation that comprises a compound or mixture of compounds that inhibits one or more intracellular signaling mechanism that regulate axon degeneration or growth cone collapse. The screening method aspect of the invention identifies test compounds that can be used for the treatment or prevention of neurodegenerative disorders based on the test compound's ability to inhibit axon degeneration or growth cone collapse.
Owner:WESTERN UNIV OF HEALTH SCI
Fucoidans as Ligands for the Diagnosis of Degenerative Pathologies
InactiveUS20120183475A1In-vivo radioactive preparationsSugar derivativesAbnormal tissue growthReperfusion injury
The present invention relates to the diagnosis of clinical conditions characterized by undesirable and / or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia / reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)
Transgenic mice expressing inducible human p25
ActiveUS7250551B2Promote generationReduce generationCompounds screening/testingBiocideDiseaseHuman animal
Disclosed are improved methods of treating individuals with Alzheimer's disease (AD) as well as methods to diagnose AD in an individual. Also included are compounds and methods of identifying compounds to treat AD. The present invention also discloses methods for decreasing the phosphorylation of amyloid precursor protein (APP), including inhibiting phosphorylation of amino acid residue tyrosine 668 of APP and for reducing cleavage of APP. The present invention further discloses transgenic (Tg), non-human animals and cells expressing a p25 transgene that are models of neurodegenerative diseases. Embodiments of the present invention are directed to methods wherein the Tg animals and Tg cells of the invention are used to screen for modulators of neurodegenerative disorders. The Tg animals and cells of the present invention are useful for elucidating the mechanisms of neurodegenerative disorders.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Methods of treating neurodegenerative disorders
The present invention provides a selected population of neural cells, including neural stem cells, neural progenitor cells, neural precursor cells, and progeny thereof, which neural cells are selected for an apoE4− phenotype. In some embodiments, the neural cells are further selected for an apoE3+ phenotype. The selected population of neural cells is useful in treating various disorders, such as neurodegenerative disorders and demyelination diseases. The present invention further provides methods of treating neurodegenerative disorders and demyelinating diseases, generally involving administering a subject selected cell population.
Owner:THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADS
Features
- R&D
- Intellectual Property
- Life Sciences
- Materials
- Tech Scout
Why Patsnap Eureka
- Unparalleled Data Quality
- Higher Quality Content
- 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com